QOP
FATE icon

Quinn Opportunity Partners’s Fate Therapeutics FATE Stock Holding History

Quinn Opportunity Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24K Hold
20,000
– – ﹤0.01% 359
2025
Q4 		$19.7K Hold
20,000
– – ﹤0.01% 368
2025
Q3 		$25.2K Hold
20,000
– – ﹤0.01% 326
2025
Q2 		$22.4K Buy
+20,000
New +$23.2K ﹤0.01% 350

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quinn Opportunity Partners's FATE Position: Q1 2026 in Review

Quinn Opportunity Partners held its Fate Therapeutics (FATE) position steady in Q1 2026 at 20,000 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Quinn Opportunity Partners first reported a position in FATE in Q2 2025 and has held it in 4 quarters since. The position peaked at $25.2K in Q3 2025. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Quinn Opportunity Partners held 20,000 shares of Fate Therapeutics worth $24K as of Q1 2026.
  • Quinn Opportunity Partners left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Quinn Opportunity Partners's portfolio in Q1 2026, its #359 holding.
  • Quinn Opportunity Partners first reported a position in Fate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Quinn Opportunity Partners's Fate Therapeutics position peaked at $25.2K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.